Development of an improved blood-stage malaria vaccine targeting the essential RH5-CyRPA-RIPR invasion complex
BG Williams, LDW King, D Pulido, D Quinkert… - Nature …, 2024 - nature.com
Reticulocyte-binding protein homologue 5 (RH5), a leading blood-stage Plasmodium
falciparum malaria vaccine target, interacts with cysteine-rich protective antigen (CyRPA) …
falciparum malaria vaccine target, interacts with cysteine-rich protective antigen (CyRPA) …
Blood-stage malaria vaccine candidate RH5. 1/Matrix-M in healthy Tanzanian adults and children; an open-label, non-randomised, first-in-human, single-centre …
SE Silk, WF Kalinga, J Salkeld, IM Mtaka… - The Lancet Infectious …, 2024 - thelancet.com
Background A blood-stage Plasmodium falciparum malaria vaccine would provide a second
line of defence to complement partially effective or waning immunity conferred by the …
line of defence to complement partially effective or waning immunity conferred by the …
Rational structure-guided design of a blood stage malaria vaccine immunogen presenting a single epitope from PfRH5
There is an urgent need for improved malaria vaccine immunogens. Invasion of erythrocytes
by Plasmodium falciparum is essential for its life cycle, preceding symptoms of disease and …
by Plasmodium falciparum is essential for its life cycle, preceding symptoms of disease and …
A broadly-neutralizing antibody against Ebolavirus glycoprotein that potentiates the breadth and neutralization potency of other antibodies
FR Donnellan, V Rayaprolu, P Rijal, V O'Dowd… - …, 2024 - pmc.ncbi.nlm.nih.gov
Ebolavirus disease (EVD) is caused by multiple species of Ebolavirus. Monoclonal
antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic …
antibodies (mAbs) against the virus glycoprotein (GP) are the only class of therapeutic …